Meeting
2016 Gastrointestinal Cancers Symposium
Establishment and validation of prognostic nomograms including HER2 status in metastatic gastric cancer.
Authors
Takeshi Kawakami
Divison of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan
Takeshi Kawakami , Yukiya Narita , Isao Oze , Shigenori Kadowaki , Nozomu Machida , Hiroya Taniguchi , Takashi Ura , Masashi Ando , Seiji Ito , Yasushi Yatabe , Masahiro Tajika , Yosuke Kito , Yutaka Haraguchi , Hirofumi Yasui , Kei Muro
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Prevention, Diagnosis, and Screening
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 24)
DOI
10.1200/jco.2016.34.4_suppl.24
Abstract #
24
Poster Bd #
G2
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
Lapatinib combined with ECF/x as first-line metastatic gastric cancer (GC) according to HER2 and EGFR status: A randomized placebo controlled phase II (EORTC 40071).
First Author: Markus Hermann Moehler
Poster
2018 Gastrointestinal Cancers Symposium
Is there a role for histology based treatment choice in advanced gastric cancer (GC)?
First Author: Rosalba Barile
Poster
2024 ASCO Gastrointestinal Cancers Symposium
HLX22 plus HLX02 and XELOX for first-line treatment of HER2-positive locally advanced or metastatic gastric/gastroesophageal junction cancer: A randomized, double-blind, multicenter phase 2 study.
First Author: Jin Li
Poster
2024 ASCO Gastrointestinal Cancers Symposium
The expanded indications of HER2-targeted therapies by monitoring of circulating tumor cells.
First Author: Yasuaki Kimura